ReviewWorld journal of gastroenterology2014
Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 107 citations in OpenAlex.
- Effect of okara and biovalorised okara consumption on postprandial amino acid response: a crossover randomised controlled trial.European journal of clinical nutrition · 2026Trial
- Evolution, structural diversity and functional plasticity of plant derived multifunctional proteases and α-amylases inhibitors.Plant molecular biology · 2026Review
- Gap Analysis of Metabolic Conversions of Off-Flavors and Antinutrients in Plant-Based Substrates.Comprehensive reviews in food science and food safety · 2026Review
- Climate change and the antinutrient-antioxidant puzzle in common bean seeds.Journal of the science of food and agriculture · 2026Review
- Article
- Gene expression and evolution of Bowman-Birk protease inhibitors in wild and domesticatedFrontiers in plant science · 2025Article
- A new Bowman-Birk type protease inhibitor regulated by MeJA pathway in maize exhibits anti-feedant activity against the Ostrinia furnacalis.Plant molecular biology · 2024Article
- A Novel Trypsin Kunitz-Type Inhibitor from Cajanus cajan Leaves and Its Inhibitory Activity on New Cancer Serine Proteases and Its Effect on Tumor Cell Growth.The protein journal · 2024Article
- Novel Stable Protease Inhibitor fromACS omega · 2024Article
- Natural Compounds as Protease Inhibitors in Therapeutic Focus on Cancer Therapy.Anti-cancer agents in medicinal chemistry · 2024Review
- Enhancing health and therapeutic potential: innovations in the medicinal and pharmaceutical properties of soy bioactive compounds.Frontiers in pharmacology · 2024Review
- An Updated Review of Soy-Derived Beverages: Nutrition, Processing, and Bioactivity.Foods (Basel, Switzerland) · 2023Review
- The effect of radiofrequency heat treatment on trypsin inhibitor activity and in vitro digestibility of soybean varieties (Journal of food science and technology · 2022Article
- Protease Inhibitors from Plants as Therapeutic Agents- A Review.Plant foods for human nutrition (Dordrecht, Netherlands) · 2022Review
- Revisiting the Domestication Process of AfricanPlants (Basel, Switzerland) · 2022Review
- Intestinal effect of faba bean fractions in WD-fed mice treated with low dose of DSS.PloS one · 2022Article
- Isolation and evaluation of quinoa (Current research in food science · 2022Article
- New Alternatives to Milk From Pulses: Chickpea and Lupin Beverages With Improved Digestibility and Potential Bioactivities for Human Health.Frontiers in nutrition · 2022Article
- The Updated Review on Plant Peptides and Their Applications in Human Health.International journal of peptide research and therapeutics · 2022Review
- Rational design of hyperstable antibacterial peptides for food preservation.NPJ science of food · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Aberrant functioning of serine proteases in inflammatory and carcinogenic processes within the gastrointestinal tract (GIT) has prompted scientists to investigate the potential of serine protease inhibitors, both natural and synthetic, as modulators of their proteolytic activities. Protease inhibitors of the Bowman-Birk type, a major protease inhibitor family in legume seeds, which inhibit potently and specifically trypsin- and chymotrypsin-like proteases, are currently being investigated as colorectal chemopreventive agents. Physiologically relevant amounts of Bowman-Birk inhibitors (BBI) can reach the large intestine in active form due to their extraordinary resistance to extreme conditions within the GIT. Studies in animal models have proven that dietary BBI from several legume sources, including soybean, pea, lentil and chickpea, can prevent or suppress carcinogenic and inflammatory processes within the GIT. Although the therapeutic targets and the action mechanism of BBI have not yet been elucidated, the emerging evidence suggests that BBI exert their preventive properties via protease inhibition; in this sense, serine proteases should be considered as primary targets in early stages of carcinogenesis. The validation of candidate serine proteases as therapeutic targets together with the identification, within the wide array of natural BBI variants, of the most potent and specific protease inhibitors, are necessary to better understand the potential of this protein family as colorectal chemopreventive agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.